IP Library Granted Patent US 11,826,390
Granted Patent B2
US 11,826,390 · App. 17/418,440 · Granted Nov 28, 2023

Materials and methods for inhibiting a viral infection, including a coronavirus infection

Inventors: Nicholas T. Monsul (Sarasota, FL); Eva A. Berkes (Sarasota, FL); Frederick T. Boehm (Sarasota, FL); Yu-Hsien Liao (Sarasota, FL)
Assignee: QUORUM INNOVATIONS, LLC
A61K35/747A61K38/164A61K45/06A61P31/14C07K14/335C12N1/205C12R2001/225
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,826,390
App. No.
17/418,440
Granted
Nov 28, 2023
Kind
B2
Abstract

The subject invention provides compositions and methods for inhibiting viral infections. Preferred embodiments of the invention provide pharmaceutical compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof.

Claims (13)

1. A method of inhibiting a viral infection in a subject in need thereof, wherein the method comprises administering to the subject in need of such viral inhibition, a virally inhibiting effective amount of a composition comprising an isolated bioactive Lactobacillus fermentum bacterial strain grown as biofilm, and/or comprising a virus-inhibiting extract of said biofilm, wherein the Lactobacillus fermentum strain is Lactobacillus fermentum Qi6 having Accession No. PTA-122195.

2. The method of claim 1 , wherein the virus is an RNA virus.

3. The method of claim 2 , wherein the virus is coronavirus.

4. The method of claim 2 , wherein the coronavirus is SARS-CoV-2.

5. The method of claim 2 , wherein the coronavirus is SARS-CoV.

6. The method of claim 2 , wherein the coronavirus is MERS-CoV.

7. The method of claim 1 , wherein the composition is administered via a parental, oral, sublingual, nasal or pulmonary route.

8. The method of claim 7 , wherein the parental route is selected from subcutaneous, intradermal, subdermal, intraperitoneal and intravenous injection.

9. The method of claim 1 , wherein the composition is administered via nasal administration.

10. The method of claim 1 , wherein the composition is administered in combination with one or more other antiviral therapies.

11. The method of claim 1 , wherein the subject is a human.

12. The method of claim 1 , comprising administering to the subject a therapeutically effective amount of the extract of the bacterial strain.

13. The method of claim 1 , wherein the composition is administered via a ventilator.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2025
From: QUORUM INNOVATIONS, LLC
To: QUORUM INNOVATIONS, INC.
Reel/Frame 072547/0227 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2021
From: MONSUL, NICHOLAS T.; BERKES, EVA A.; BOEHM, FREDERICK T.; LIAO, YU-HSIEN
To: QUORUM INNOVATIONS, LLC
Reel/Frame 057006/0675 →
Continuity (2)
Provisional Application 63035733 · Jun 6, 2020
Related Publication 20230136276A1 · May 4, 2023
Cited By (1)
US 12,495,800